Economy/Home · Economy

Yuhan Corporation Shares Rise 3.4% to 79,000 Won... IBK Investment & Securities Maintains 'Buy' Despite Lowering Target Price to 110,000 Won

Yuhan Corporation (000100) showed an upward trend during trading on the 16th. The stock price rose 3.4% from the previous day to 79,000 won. On the same day, IBK Investment & Securities lowered its target price for Yuhan Corporation by 50,000 won, from 160,000 won to 110,000 won. The adjustment amo

Wooil Shim
Staff Reporter
6 min read
Yuhan Corporation Shares Rise 3.4% to 79,000 Won... IBK Investment & Securities Maintains 'Buy' Despite Lowering Target Price to 110,000 Won
CBC News

Yuhan Corporation (000100) showed an upward trend during trading on the 16th. The stock price rose 3.4% from the previous day to 79,000 won.

On the same day, IBK Investment & Securities lowered its target price for Yuhan Corporation by 50,000 won, from 160,000 won to 110,000 won. The adjustment amounts to 31.25% of the previous target price. However, the investment opinion was maintained at 'Buy.' Despite the lowered target price, the stock rose, drawing market attention to the value of new drug royalties and future earnings outlook.

Adoption of SOTP Method... Pharmaceutical and CDMO Businesses Valued at 2.6 Trillion Won, Lazertinib Royalties at 4 Trillion Won

IBK Investment & Securities explained that it changed its target price calculation method to SOTP (Sum of the Parts), which values each business segment separately and sums them.

Accordingly, the pharmaceutical and contract development and manufacturing (CDMO) business was valued at 2.6 trillion won, and the royalties from Lazertinib, a treatment for non-small cell lung cancer, were valued at 4 trillion won. The value of the new drug candidate YH35324 was estimated at 576 billion won. A simple sum of the three segments amounts to 7.176 trillion won.

Notably, the royalty value of Lazertinib exceeded the value of the pharmaceutical and CDMO businesses, highlighting the proportion of new drug-related revenue in the company's valuation.

Target Price of 110,000 Won... About 39.2% Above Current Share Price

The difference between the intraday share price of 79,000 won and the revised target price of 110,000 won is 31,000 won, about 39.2% above the current share price. However, the target price is the securities firm's estimate and does not mean the actual share price will reach that level.

It is worth noting that the buy opinion was maintained despite the lowered target price. This is because the change in valuation methodology and any change in investment opinion should be examined separately.

Key Points Ahead... Realization of Lazertinib Royalties Is a Core Variable

In future valuations of Yuhan Corporation, key variables are expected to include whether Lazertinib royalty revenue materializes and its scale, the profitability of the existing pharmaceutical business, and the development progress of new drug candidates.

Meanwhile, it has not been confirmed whether the day's stock price increase was due to the securities firm's revised valuation. Share price movements and changes in corporate valuation need to be interpreted separately.

[This article was written based on publicly available market information and securities firm analysis, and does not recommend buying or selling any specific stock. Share prices and target prices may change depending on market conditions and corporate performance. Investment decisions and responsibilities lie with the investor, and AI assistance was used in the writing of this article.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.